Doximity

Wells Fargo

Wells Fargo Downgrades Doximity to Overweight, PT Lowered to $45.

JP Morgan upgrades Doximity to Neutral, lowers PT to $40 from $62.

Doximity Q4 CY2025 Results Top Revenue Expectations but Guidance Falls Short.

Morgan Stanley Maintains Overweight Rating on Doximity with Lower PT of $49

Doximity: Piper Sandler Downgrades to Overweight, PT to $40 from $70.

Catalyst<ul> <li>Extra-large institutional fund flows are positive, suggesting significant capital interest in DOCS.</li></ul>Risk<ul> <li>Technical indicators show bearish signals are dominant with no recent bullish patterns, indicating a potentially weak near-term trend.</li> <li>Market expectations remain pessimistic and analyst ratings show differences, highlighting uncertainty about DOCS's direction.</li></ul>

Key Factors

Doximity (DOCS) reported Q3 revenue of $185.05 million, a 10% year-over-year increase, with adjusted earnings per share of $0.46. The company provided Q4 revenue guidance of $143 million to $144 million, below analyst estimates, citing delayed pharmaceutical budgets and increased AI infrastructure spending. Doximity's Q3 adjusted EBITDA reached $111.4 million, reflecting a 60% margin, while workflow products reached 720,000 users. Multiple brokerages including Wells Fargo, JP Morgan, and Piper Sandler downgraded or adjusted their price targets for DOCS, lowering PTs to between $37 and $49.

DOCS News